Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Belgium

Research and Innovation Action · Running

PregInPoxVac Maternal and Infant Safety and Immunogenicity in a Phase 3, Open-label, Randomised, Vaccine Trial of a Two-dose Mpox Vaccine

Coordinator
Universiteit Antwerpen, Belgium
Runs
1 August 2024 to 31 July 2027
Status
Running
EU funding
€1.6m
Total cost
€1.6m
Partners
4 organisations in 4 countries
Type
Research and Innovation Action
Grant agreement
101195533

What the project is doing

In the project's own words, from its summary on CORDIS.

Mpox can cause severe complications in vulnerable groups such as pregnant women and children, necessitating targeted public health interventions and vaccine trials in these populations. Limited data suggest the MVA-BN vaccine is safe for pregnant women and likely poses no risk to breastfed infants, but comprehensive human data are lacking. Trials in endemic areas are crucial for evaluating the vaccine's safety and efficacy in real-world settings.

Vaccine hesitancy, exacerbated by misinformation and distrust in healthcare systems, poses a significant challenge, especially in the Democratic Republic of the Congo. Pregnant women are particularly affected by concerns about vaccine safety, which influences their willingness to vaccinate. Addressing these concerns through targeted communication and community engagement is vital. A proposed phase 3, randomized trial will assess the safety and immunogenicity of the MVA-BN vaccine in healthy pregnant and postpartum women and in infants/children (6-24 months old).

Additionally, a qualitative study on vaccine hesitancy will inform the trial design and implementation, aiming to enhance vaccination uptake in these high-risk groups.

Who is involved

OrganisationCityCountryRole
Universiteit AntwerpenAntwerpenBelgiumCoordinator
Universite De KinshasaKinshasaCDParticipant
Fondazione Penta EtsPadovaItalyParticipant
Africa Clinical Research ManagementlimitedKisumuKenyaParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI